, Volume 181, Issue 1–2, pp 89–95 | Cite as

Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran

  • Saham Ansari
  • Mohammad T. Hedayati
  • Kamiar Zomorodian
  • Keyvan Pakshir
  • Hamid Badali
  • Abdollah Rafiei
  • Mostafa Ravandeh
  • Seyedmojtaba Seyedmousavi


Dermatophytosis is a common mycotic infection of the skin, nail, and hair, associated with major public health concern worldwide. Various species of dermatophytes show significant differences in susceptibility to antifungals. Here, we present the antifungal susceptibility of a large collection of molecularly identified dermatophyte isolates obtained from tropical region of south of Iran. A total of 9485 patients clinically suspected to have cutaneous fungal infections were examined. Dermatophytosis was confirmed in 1502 cases by direct microscopy and culture. Three hundred and sixteen isolates recovered in culture were identified to species level using PCR sequencing of ITS region and RFLP. Tinea corporis was the most prevalent type of clinical manifestation (35.2 %), followed by tinea cruris (17 %), tinea capitis (12.8 %), tinea pedis (11.3 %), tinea manuum (11 %), tinea unguium (6.9 %), and tinea barbae (5.8 %). Trichophyton interdigitale was the most common isolate (49.36 %), followed by Trichophyton rubrum (18.98 %), Epidermophyton floccosum (13.29 %), Microsporum canis (9.17 %), Arthroderma benhamiae (T. anamorph of A. benhamiae; 5.38 %), and Trichophyton tonsurans (3.79 %). Overall, irrespective of the geographical region, terbinafine was the most potent antifungal against all isolates, with an MIC range of 0.002–0.25 μg/mL, followed by itraconazole (0.004–0.5 μg/mL), griseofulvin (0.125–8 μg/mL), and fluconazole (4–128 μg/mL). Analysis of our data revealed a significant increase in the frequency of A.benhamiae, which definitely warrants further investigation to explore source of this infection in south of Iran. Moreover, terbinafine was the most effective antifungal against all isolates, in vitro.


Dermatophytosis Molecular identification Antifungal susceptibility South of Iran Arthroderma benhamiae 



The participating patients are thanked for their kind cooperation, which was essential for the completion of the study. This study was supported by Invasive Fungi Research Center, Mazandaran University of Medical Sciences, Sari (Iran).


  1. 1.
    Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996; 34(2 Pt 1):282–286.Google Scholar
  2. 2.
    Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.CrossRefPubMedGoogle Scholar
  3. 3.
    Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2015;41(3):374–88.CrossRefPubMedGoogle Scholar
  4. 4.
    White TC, Oliver BG, Graser Y, Henn MR. Generating and testing molecular hypotheses in the dermatophytes. Eukaryot Cell. 2008;7(8):1238–45.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Graser Y, Scott J, Summerbell R. The new species concept in dermatophytes-a polyphasic approach. Mycopathologia. 2008;166(5–6):239–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Gupta AK, Hofstader SL, Adam P, Summerbell RC. Tinea capitis: an overview with emphasis on management. Pediatr Dermatol. 1999;16(3):171–89.CrossRefPubMedGoogle Scholar
  7. 7.
    Macura AB, Filip E, Pawlik B. Evaluation of susceptibility of dermatophytes to antifungal drugs. Med Dosw Mikrobiol. 1993;45(2):253–7.PubMedGoogle Scholar
  8. 8.
    Korting HC, Rosenkranz S. In vitro susceptibility of dermatophytes from Munich to griseofulvin, miconazole and ketoconazole. Mycoses. 1990;33(3):136–9.PubMedGoogle Scholar
  9. 9.
    Yenisehirli G, Tuncoglu E, Yenisehirli A, Bulut Y. In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey. Int J Dermatol. 2013;52(12):1557–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Fernandez-Torres B, Cabanes FJ, Carrillo-Munoz AJ, et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol. 2002;40(11):3999–4003.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Santos DA, Barros ME, Hamdan JS. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol. 2006;44(1):98–101.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Carrillo-Munoz AJ, Quindos G, Ruesga M, et al. In vitro antifungal susceptibility testing of filamentous fungi with sensititre yeast one. Mycoses. 2006;49(4):293–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Naseri A, Fata A, Najafzadeh MJ, Shokri H. Surveillance of dermatophytosis in northeast of Iran (Mashhad) and review of published studies. Mycopathologia. 2013;176(3–4):247–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Chadeganipour M, Mohammadi R, Shadzi S. A 10-year study of dermatophytoses in Isfahan, Iran. J Clin Lab Anal. 2015. doi: 10.1002/jcla.21852.
  15. 15.
    Omidynia E, Farshchian M, Sadjjadi M, Zamanian A, Rashidpouraei R. A study of dermatophytoses in Hamadan, the governmentship of West Iran. Mycopathologia. 1996;133(1):9–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Chadeganipour M, Shadzi S, Dehghan P, Movahed M. Prevalence and aetiology of dermatophytoses in Isfahan, Iran. Mycoses. 1997;40(7–8):321–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Abastabar M, Rezaei-Matehkolaei A, Shidfar MR, et al. A Molecular epidemiological survey of clinically important dermatophytes in Iran based on specific RFLP profiles of beta-tubulin gene. Iran J Public Health. 2013;42(9):1049–57.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Rezaei-Matehkolaei A, Makimura K, De Hoog S, et al. Molecular epidemiology of dermatophytosis in Tehran, Iran, a clinical and microbial survey. Med Mycol. 2013;51(2):203–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Mahmoudabadi AZ. A study of dermatophytosis in South West of Iran (Ahwaz). Mycopathologia. 2005;160(1):21–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Aghamirian MR, Ghiasian SA. Dermatophytoses in outpatients attending the Dermatology Center of Avicenna Hospital in Qazvin, Iran. Mycoses. 2008;51(2):155–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Alizadeh N, Sadr-Ashkevari S, Golchai J, Maboodi A, Falahati AA. Descriptive study of dermatophytosis in Guilan. Iran J Dermatol. 2004;7:255–60.Google Scholar
  22. 22.
    Mahboubi A, Baghestani SH, Hamedi Y, Heydari M, Vahdani M. Epidemiology of dermatophytosis in Bandar Abbas, Iran (2003–2004). Med J Hormozgan Univ. 2006;9:227–34.Google Scholar
  23. 23.
    Pakshir K, Hashemi J. Dermatophytosis in Karaj, Iran. Indian J Dermatol. 2006;51:262–4.CrossRefGoogle Scholar
  24. 24.
    Sepahvand A, Abdi J, Shirkani Y, Fallahi S, Tarrahi M, Soleimannejad S. Dermatophytosis in western part of Iran, Khorramabad. Asian J Biol Sci. 2009;2:58–65.CrossRefGoogle Scholar
  25. 25.
    Bassiri-Jahromi S, Khaksari AA. Epidemiological survey of dermatophytosis in Tehran, Iran, from 2000 to 2005. Indian J Dermatol Venereol Leprol. 2009;75:142–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Rezvani SM, Sefidgar SaA, Hasanjani-Roushan M. Clinical patterns and etiology of dermatophytosis in 200 cases in Babol, North of Iran. Casp J Intern Med. 2010;1:23–6.Google Scholar
  27. 27.
    Sadeghi G, Abouei M, Alirezaee M. A 4-year survey of dermatomycoses in Tehran from 2006 to 2009. J Mycol Med. 2011;21:260–5.CrossRefGoogle Scholar
  28. 28.
    Ghannoum MA, Wraith LA, Cai B, Nyirady J, Isham N. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. Br J Dermatol. 2008;159(3):711–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Makimura K, Tamura Y, Mochizuki T, et al. Phylogenetic classification and species identification of dermatophyte strains based on DNA sequences of nuclear ribosomal internal transcribed spacer 1 regions. J Clin Microbiol. 1999;37(4):920–4.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Rezaei-Matehkolaei A, Makimura K, Shidfar M, et al. Use of single-enzyme PCR-restriction digestion barcode targeting the internal transcribed spacers (ITS rDNA) to identify dermatophyte species. Iran J Public Health. 2012;41(3):82–94.PubMedCentralPubMedGoogle Scholar
  31. 31.
    CLSI. Reference method for broth dilution antifungal susceptibilitytesting of filamentous Fungi; Approved standard, 2nd edition. CLSI Document. M38-A2. Clinical and laboratory Standards Institute, Wane (2008).Google Scholar
  32. 32.
    Ellabib MS, Khalifa Z, Kavanagh K. Dermatophytes and other fungi associated with skin mycoses in Tripoli, Libya. Mycoses. 2002;45(3–4):101–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Maulingkar SV, Pinto MJ, Rodrigues S. A clinico-mycological study of dermatophytoses in Goa, India. Mycopathologia. 2014;178(3–4):297–301.CrossRefPubMedGoogle Scholar
  34. 34.
    Symoens F, Jousson O, Packeu A, et al. The dermatophyte species Arthroderma benhamiae: intraspecies variability and mating behaviour. J Med Microbiol. 2013;62(Pt 3):377–85.CrossRefPubMedGoogle Scholar
  35. 35.
    Chadeganipour M, Nilipour S, Havaei A. In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan. Mycoses. 2004;47(11–12):503–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Pakshir K, Bahedinie L, Rezaei Z, Sodaifi M, Zomorodian K. In vitro activity of six antifungal drugs against clinically important dermatophytes. Jundishapur J Microbiol. 2009;2:158–63.Google Scholar
  37. 37.
    Nowrozi H, Nazeri G, Adimi P, Bashashati M, Emami M. Comparison of the activities of four antifungal agents in an in vitro model of dermatophytes nail infection. Indian J dermatol. 2008;53:125–8.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Adimi P, Hashemi SJ, Mahmoudi M, et al. In-vitro Activity of 10 Antifungal Agents against 320 dermatophyte strains using microdilution method in Tehran. Iran J Pharm Res. 2013;12(3):537–45.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Fernandez-Torres B, Carrillo AJ, Martin E, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother. 2001;45(9):2524–8.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Da Silva Barros ME, De Assis Santos D, Hamdan JS. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol. 2007;56(Pt 4):514–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Araujo CR, Miranda KC, Fernandes Ode F, Soares AJ, Silva Mdo R. In vitro susceptibility testing of dermatophytes isolated in Goiania, Brazil, against five antifungal agents by broth microdilution method. Rev Inst Med Trop Sao Paulo. 2009;51(1):9–12.Google Scholar
  42. 42.
    Silva LB, De Oliveira DB, Da Silva BV, et al. Identification and antifungal susceptibility of fungi isolated from dermatomycoses. J Eur Acad Dermatol Venereol. 2014;28(5):633–40.CrossRefPubMedGoogle Scholar
  43. 43.
    Azambuja CV, Pimmel LA, Klafke GB, Xavier MO. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum. An Bras Dermatol. 2014;89(4):581–6.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol. 2003;41(10):4817–9.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Itoi S, Kano R, Hasegawa A, Kamata H. In vitro activities of antifungal agents against clinical isolates of dermatophytes from animals. J Vet Med Sci. 2012;74(8):1067–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610–6.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Grover C, Arora P, Manchanda V. Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis. Int J Dermatol. 2012;51(4):455–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Saham Ansari
    • 1
    • 2
  • Mohammad T. Hedayati
    • 1
    • 2
  • Kamiar Zomorodian
    • 3
  • Keyvan Pakshir
    • 3
  • Hamid Badali
    • 1
    • 2
  • Abdollah Rafiei
    • 4
  • Mostafa Ravandeh
    • 3
  • Seyedmojtaba Seyedmousavi
    • 1
    • 5
    • 6
  1. 1.Invasive Fungi Research CenterMazandaran University of Medical SciencesSariIran
  2. 2.Department of Medical Mycology and Parasitology School of MedicineMazandaran University of Medical SciencesSariIran
  3. 3.Department of Parasitology and Mycology, Basic Sciences in Infectious Diseases Research Center, School of MedicineShiraz University of Medical SciencesShirazIran
  4. 4.Department of Parasitology and Mycology/Infectious and Tropical Medicine Research CenterAhvaz Jundishapur University of Medical SciencesAhvazIran
  5. 5.Department of Medical Microbiology and Infectious DiseasesErasmus University Medical CenterErasmusThe Netherlands
  6. 6.Department of Medical MicrobiologyRadboud University Medical CentreNijmegenThe Netherlands

Personalised recommendations